Jayne D, et al. - In this multicenter, double-blind, placebo-controlled study, authors investigated the safety and effectiveness of belimumab as adjunctive therapy in the maintenance of remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis cases. They observed no decrease in the risk of a protocol-specified event (PSE) or vasculitis relapse while managing with belimumab vs placebo. They noted the overall rate of PSEs low (11 [21.2%] of 52 subjects receiving placebo, 10 [18.9%] of 53 cases receiving belimumab). In the placebo group (n = 8), vasculitis relapse occurred independently of the induction regimen, disease stage, or ANCA type. They noticed the occurrence of vasculitis relapses (in the belimumab group, n = 6) in subjects who had PR3-ANCA–associated vasculitis with cyclophosphamide-induced disease remission. They reported adverse events in 92.5% of 53 candidates who received belimumab vs 82.7% of 52 cases receiving placebo.